Summary of Key Points
Economist Gao Shanwen passed away due to a rare form of vascular immunoblastic T-cell lymphoma (AITL), highlighting the harsh realities of diagnosing and treating difficult cancers. Even those with access to top-tier resources and high levels of awareness are not immune to misdiagnosis, delays in treatment, the risks associated with trial-and-error approaches, the high barriers to accessing necessary resources, and the limitations of medical science. AITL is a rare disease characterized by difficulties in diagnosis and limited treatment options, leaving patients' fates largely at the mercy of chance and the timely discovery of the right treatment path.
1. Misdiagnosis: Treating Cancer as a Common Illness
The early symptoms of AITL—night sweats, swollen lymph nodes, and fever—are very similar to those of the flu, infections, or skin diseases, making it easy to misdiagnose the condition. Gao Shanwen spent 10 months from the onset of his symptoms until a definitive diagnosis was made because multiple hospitals in Beijing did not consider lymphoma as a possibility. Another patient's father was initially treated for influenza and only received proper examination when his fever reached 41 degrees Celsius after more than a month of treatment.
Why are misdiagnoses so common? Firstly, AITL is extremely rare (accounting for 2.66% of lymphoma cases), and many doctors have never encountered it before. Secondly, the symptoms are non-specific; for example, some patients develop rashes, which may lead doctors to refer them to dermatologists rather than hematological oncologists. Thirdly, the testing capabilities in primary hospitals are limited, and pathological samples must be sent to provincial-level hospitals, further delaying the diagnosis process.
The consequences of misdiagnosis can be fatal; without an accurate diagnosis, appropriate treatment cannot be administered, and by the time cancer is identified, it may already be in an advanced stage, missing the optimal window for treatment. As Dr. Li Dinggang said, "A misdiagnosis leads to incorrect treatment, incorrect treatment results in trial and error, and trial and error often ends in death."
2. Treatment: Every Step Is a Life-and-Death Challenge
Even after a correct diagnosis, the treatment process is fraught with risks. There is currently no specific drug for AITL, and the first-line chemotherapy regimen (CHOP) is ineffective for many patients. The only options are experimental new drugs or participating in clinical trials, but the outcomes are uncertain.
For instance, while CAR-T therapy has proven effective against B-cell lymphoma, it is challenging to use for T-cell lymphoma because both the cancer cells and the immune cells used in the treatment are T-cells, which can lead to self-destruction and potentially severe cytokine storms (excessive immune responses causing organ failure). Hematopoietic stem cell transplantation represents a last hope, but it requires the patient's condition to be in complete remission, which many patients do not achieve (Gao Shanwen did not live long enough to receive this treatment).
Even if the treatment phase is successfully overcome, infections can still be deadly. For example, Xiao Ba's father died after being infected with Pseudomonas aeruginosa while in the ICU following a successful CAR-T procedure. Doctors emphasize that our understanding of AITL is still far from advanced enough to ensure a simple and effective cure; every step in the treatment process carries the risk of error.
3. Access to Treatment: Only Those With Resources Can Survive
The resources available for treating rare diseases are limited, acting like a narrow gate that only a few can pass through. For instance, traveling to Shanghai for a transplant requires preparing a budget of 500,000 yuan, in addition to the costs of upfront chemotherapy (200,000 yuan). This is an overwhelming burden for ordinary families. Li Li's mother had to opt for conservative treatment at a local hospital due to financial and logistical constraints, foregoing CAR-T therapy.
Even with money, access to information and connections can be crucial. Xiao Ba, being in the tech industry, spent the night researching all available cases and visited major hospitals in Guangzhou and Shenzhen to find a suitable CAR-T treatment option. For ordinary people, however, they may not even know what CAR-T therapy is, let alone have access to clinical trials.
Excessive resources can also be detrimental; Gao Shanwen's special status led to him being referred to many experts, but this sometimes hindered the diagnosis process as doctors were hesitant to consider a malignant lymphoma from the outset.
4. The Limits of Medicine and Awareness: Luck Plays a Crucial Role
The 5-year survival rate for AITL is only 30%, indicating that 70% of patients do not survive more than five years. Despite having money, access to knowledge, and the best doctors, the limitations of medical science remain significant. As Dr. Zhuo Guangsong pointed out, missing the optimal treatment window means that even high-end resources can only increase the chances of survival, but cannot eliminate the inherent severity of the disease.
In summary, when facing a difficult cancer, the best things you can do are to seek treatment at a large hospital as early as possible, consult multiple specialists, and try to obtain the latest information. However, whether you survive ultimately depends largely on luck—just like rolling a die; you never know which outcome will happen.
Final Thoughts
Gao Shanwen's story reminds us that even those at the top of society can be powerless in the face of a serious illness. For the general public, it is important to seek medical attention promptly if symptoms persist or worsen, to understand basic medical knowledge, and to avoid being misled by incorrect information. If diagnosed with a rare disease, it is crucial to consult a specialist (such as a hematologist) to avoid wasting time at minor clinics.
Time is life, and life cannot afford the cost of trial and error.